Achilles Therapeutics

1.48
0.00 (0.00%)
At close: Mar 20, 2025, 3:59 PM

Achilles Therapeutics Statistics

Share Statistics

Achilles Therapeutics has 41.1M shares outstanding. The number of shares has increased by 0.03% in one year.

Shares Outstanding 41.1M
Shares Change (YoY) 0.03%
Shares Change (QoQ) 0%
Owned by Institutions (%) 60.1%
Shares Floating 20.06M
Failed to Deliver (FTD) Shares 7.74K
FTD / Avg. Volume 0.62%

Short Selling Information

The latest short interest is 159.25K, so 0.39% of the outstanding shares have been sold short.

Short Interest 159.25K
Short % of Shares Out 0.39%
Short % of Float 0.42%
Short Ratio (days to cover) 1.69

Valuation Ratios

The PE ratio is undefined and the forward PE ratio is -9.46. Achilles Therapeutics's PEG ratio is undefined.

PE Ratio undefined
Forward PE -9.46
PS Ratio 0
Forward PS null
PB Ratio 0.25
P/FCF Ratio undefined
PEG Ratio undefined
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Achilles Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.57, with a Debt / Equity ratio of undefined.

Current Ratio 8.57
Quick Ratio 8.57
Debt / Equity undefined
Debt / EBITDA -
Debt / FCF -
Interest Coverage undefined

Financial Efficiency

Return on Equity is -0.49% and Return on Invested Capital is -51.56%.

Return on Equity -0.49%
Return on Assets -0.43%
Return on Invested Capital -51.56%
Revenue Per Employee $0
Profits Per Employee $-341.5K
Employee Count 204
Asset Turnover 0
Inventory Turnover 4.73M

Taxes

Income Tax 491K
Effective Tax Rate -0.01%

Stock Price Statistics

The stock price has increased by 18.4% in the last 52 weeks. The beta is 1.25, so Achilles Therapeutics's price volatility has been higher than the market average.

Beta 1.25
52-Week Price Change 18.4%
50-Day Moving Average 1.32
200-Day Moving Average 1.02
Relative Strength Index (RSI) 76.37
Average Volume (20 Days) 1.25M

Income Statement

Revenue n/a
Gross Profit -4.73M
Operating Income -75.25M
Net Income -69.67M
EBITDA -70.44M
EBIT n/a
Earnings Per Share (EPS) -1.74
Full Income Statement

Balance Sheet

The company has 131.54M in cash and 4.62M in debt, giving a net cash position of 126.92M.

Cash & Cash Equivalents 131.54M
Total Debt 4.62M
Net Cash 126.92M
Retained Earnings -259.95M
Total Assets 122.68M
Working Capital 93.16M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -48.45M and capital expenditures -1.1M, giving a free cash flow of -49.55M.

Operating Cash Flow -48.45M
Capital Expenditures -1.1M
Free Cash Flow -49.55M
FCF Per Share -1.24
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

ACHL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -117.57%
FCF Yield -81.46%
Dividend Details

Analyst Forecast

The average price target for ACHL is $4, which is 170.3% higher than the current price. The consensus rating is "Hold".

Price Target $4
Price Target Difference 170.3%
Analyst Consensus Hold
Analyst Count 2
Stock Forecasts

Scores

Altman Z-Score -2.67
Piotroski F-Score 1